Search Results

MC# 19-11
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria

MC# 19-16
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients with Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

MC# 19-22
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma

MC# 19-30
Phase Ib/II Open-Label Study Evaluating Tazemetostat in Combination with Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects with Metastatic Castration Resistant Prostate Cancer

MC# 19-32
A Phase I Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy

MC# 19-34
A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies Involving the Central Nervous System (CNS)

MC# 19-40
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

MC# 20-03
A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

MC# 20-22
An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation

MC# 17-04
Phase I/II Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNb-NIS), Monotherapy and in Combination With Avelumab in Patients with Refractory Solid Tumors

MC# 18-15
A Phase I-II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies

MC# 18-22
A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 60 mg/m2 Administered during a 60-minute Infusion on Cardiac Repolarization in 6 Patients with Advanced Solid Tumors.

MC# 19-10
A Phase Ib Study of ARQ 751 as a Single Agent or in Combination with Other Anti-cancer Agents in Adult Subjects with Advanced Solid Tumors with PIK3CA/AKT/PTEN Mutations

MC# 19-13
A Phase I Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral (IT) Injection in Patients with Advanced/Metastatic Solid Tumors

MC# 19-27
A Phase I Study of AGEN2373, an Anti-CD137 Monoclonal Antibody in Subjects with Advanced Cancer

MC# 20-02
An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients with Solid Tumors

MC# 16-39
Phase I Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas

MC# 19-04
Phase I Study of KN026 in HER2 Expressing Breast Cancer, Gastric/Gastroesophageal Junction Cancer and other Locally Advanced/Metastatic Solid Tumors

MC# 19-05
A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

MC# 20-09
A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients with Solid Tumors Likely to Express NaPi2b

MC# 19-09
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

MC# 19-33
A Phase I, Open-label Single-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects with Moderate and Severe Hepatic Impairment with Advanced Malignancies

MC# 19-38
A Phase I Study of GS-1423 in Subjects with Advanced Solid Tumors

MC# 15-03
A Phase I/II, Open-Label, Dose Escalation, Safety, and Tolerability Study of INCB054828 in Subjects with Advanced Malignancies

MC# 19-12
Phase I/II Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)